Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
77.05
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
Next >
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
June 30, 2023
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...
Via
Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
June 22, 2023
These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers.
Via
InvestorPlace
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
June 14, 2023
Via
Benzinga
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
May 26, 2023
Via
Benzinga
Death Cross Looms Over Biomarin Pharmaceutical Investors
May 02, 2023
Via
Benzinga
What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical
April 27, 2023
Via
Benzinga
A Preview Of Biomarin Pharmaceutical's Earnings
April 25, 2023
Via
Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
March 21, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 25, 2023
Via
Benzinga
3 Biotech Stocks With Blockbuster Potential
May 24, 2023
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.
Via
InvestorPlace
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
May 17, 2023
The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
April 20, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
Preview: Biomarin Pharmaceutical's Earnings
February 24, 2023
Via
Benzinga
Analyst Ratings for Biomarin Pharmaceutical
February 22, 2023
Via
Benzinga
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
March 30, 2023
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.
Via
Investor's Business Daily
3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize
March 28, 2023
The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story.
Via
The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
March 21, 2023
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
March 08, 2023
Via
Benzinga
Why BioMarin Shares Are Plunging Today?
March 06, 2023
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.
Via
Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
March 06, 2023
The company is testing a drug for children with achondroplasia, a cause of dwarfism.
Via
Investor's Business Daily
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
March 03, 2023
On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier.
Via
Investor's Business Daily
uniQure Stock Trying To Close In On Key Technical Measure
February 28, 2023
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.
Via
Investor's Business Daily
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
February 28, 2023
Via
Benzinga
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
February 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
3 Prime Healthcare Takeover Targets
February 14, 2023
These three companies are attractive targets for their potential.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.